Fig 3. Immune responses of SART3-specific T cells in HCC patients.

(A) Interferon (IFN)-γ enzyme-linked immunospot (ELISpot) assay was performed using SART3, HIVenv₅₈₄, and cytomegalovirus pp65₃₂₈-derived peptides with peripheral blood mononuclear cells (PBMCs) of HCC patients. % indicates the proportion of patients who showed positive responses. (B) IFN-γ ELISpot assay in healthy donors and disease control groups. “N” denotes normal donors. “C” denotes the patients with chronic hepatitis. “L” denotes the patients with liver cirrhosis. % shows the proportion of patients who exhibited positive responses. (C) Comparison of the mean number of SART3-derived peptide-specific spots among the three groups. Error bars indicate the standard deviations. Black and white bars indicate the frequencies of SART3₁₀₉- and SART3₃₁₅-specific T cells, respectively.